Textile converter Brand & Oppenheimer Co. Inc. (B&O) has acquired the assets of Performance Textiles Inc., a supplier of high- performance fabrics engineered for domestic and export customers. The acquisition was sponsored by Praesidian Capital, which is an investor in B&O.
The consensual acquisition will complement B&O’s textile capabilities with a diversified product line targeted to sports, recreational products, high-visibility work-wear, commercial, military and government end uses. Founded by Bill Gerrow and Peter Sullivan, Performance Textiles’ focus will continue to be safety, maximum performance, and durability, areas critical for fabrics that are destined for use in parachutes, hot air balloons, and industrial protective vests.
“Performance Textiles is a unique and well established company in our industry with similar production processes and suppliers to ours,” stated Dan Pezold, B&O president and CEO. “We believe our combined resources will benefit everyone in the textile supply chain.”
“We look forward to the new opportunities that come with joining the Brand & Oppenheimer family. Our combined resources will allow us to serve our customers with new and different textile solutions,” Gerrow stated. “What will not change, however, is the excellent service and development of textile technology solutions to which our customers have become accustomed over the past 25 years.”
Brand & Oppenheimer Co. Inc. now in its centennial year, is a supplier to the textile industry. Based in Red Bank, N.J., B&O has distinguished itself in the past 15 years as a leader in textile conversion for the U.S. military. The company’s principal owners are B&O management and Praesidian Capital.
With operations in Duxbury, Mass., and Greensboro, N.C., Performance Textiles Inc., produces high performance textile products for a variety of requirements in the commercial and military markets. During the past 25 years, the company has developed extensive experience in fabric manufacturing and quality assurance from raw materials through the final stages of treatments.